Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

The notified concentration involves a proposed transaction pursuant to which funds managed by affiliates of Centerbridge Partners, L.P. (“Centerbridge”) will, indirectly, acquire sole control over Hospital Topco Limited and entities which will become its direct and indirect subsidiaries (together, the General Healthcare Group or “GHG”). The transaction will lead to Centerbridge acquiring sole control over GHG by way of an indirect acquisition of shares, together with the amendment of the governance arrangements of GHG.

Centerbridge is an investment management firm organised in the USA focused on private equity and distressed investment opportunities.

Pursuant to the transaction, Hospital Topco will become the parent company of the UK based healthcare group that carries out its operations under the BMI Healthcare brand, and the property interest holding companies.

The proposed concentration is notified pursuant to Article 3(1)(b) of Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings because the Transaction will lead to the Target being solely controlled by Centerbridge.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.